not likely. They have 200+ million in the bank, and won't need more anytime soon. FDA approval and initial roll out will happen before the need for anymore funding. It's doubtful they'll need to get more money by dilution, but if they do need money, the price of the company will be significantly higher.
Here's one in UK a man with resistant throat gonorrhea.
Gonorrhea trial results are going to be very import.
I don't think there are many short on this stock. Honestly, I think the stock is just largely undiscovered. Given the market cap, and what similar stocks like Durata, Trius, and others were bought out for, this is really undervalued. Positive news on the phase 3 and we could be looking at share prices an order magnitude higher than they now are.
I just wasted 3 minutes of my life reading that #$%$. What kind of idiot rates a pre-release biotech on its current earnings? Exactly where do they expect earnings to come from until the drug is released?
Nah, this stock has already been decimated and is being traded near or below cash on hand. The time to accumulate is now. The stock will appreciate as the readout to P3 approaches. A successful P3 and this is trading in the teens, even in a bad market.
For a supposed jedi of pharmaceuticals, you certainly don't seem to understand the rate of growth of ABX resistance. If you did, you would understand why a drug that tests as non-inferior will soon be superior. The time to find new ABX's is while the old ones are still working but beginning to show signs of resistance. That time is now and the companies that find successful next generation ABX's that reset the resistance curves, will generate billions of dollars of revenue.
Why? AKAO looks way undervalued to me. I'm not adding today because spikes on news are usually over bought, but long term, this is a multi-bagger
Not until it recovers a fair amount of it's former high. Why? Because no company will offer want to acquire at a price the board would accept until it closer to being passed PIII. The board isn't going to want to sell in the single digits, probably not until somewhere in the 20's, and that's not happening until it looks like it has a drug that will be approved by the FDA. Slam dunk approval only happens with success on the current PIII which would push the share price to the mid 20's.